SCHEMBL29796804

SCHEMBL29796804

Oc1nccc(-c2cncs2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MYC P01106 1/20 0.39
PIM1 P11309 5/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSP90AA1 P07900 2/20 0.35
DYRK1A Q13627 2/20 0.35
CHEK1 O14757 1/20 0.35
CHEK2 O96017 1/20 0.35
CCNK O75909 1/20 0.34
CDK12 Q9NYV4 1/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
RET P07949 1/20 0.32
IMPDH2 P12268 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CD38 P28907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22895342 0.79 PIM1 (0.38) MAPTNPC1SMN1; SMN2MYCPIM1
SCHEMBL6129041 0.73 NPC1 (0.46) MAPTNPC1SMN1; SMN2MYCPIM1
SCHEMBL327377 0.73 PIM1 (0.50) MAPTNPC1SMN1; SMN2PIM1KDM4E
SCHEMBL2345970 0.73 ALDH1A1 (0.69) MAPTNPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3091105 0.72 PIM1 (0.40) MAPTPIM1HSP90AA1DYRK1ADYRK2
SCHEMBL2088047 0.70 PRKCD (0.59) MAPTNPC1PIM1DYRK1ACHEK1
SCHEMBL31112110 0.70 MAPK1 (0.40) CCNKCDK12DYRK1BMEN1KMT2A
SCHEMBL30961277 0.69 CHEK1 (0.35) MAPTMYCCHEK1CHEK2IMPDH2
SCHEMBL20455525 0.68 CDK4 (0.49) MAPTNPC1SMN1; SMN2PIM1MEN1
SCHEMBL29386286 0.68 CDK4 (0.49) MAPTNPC1SMN1; SMN2PIM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022157166-A1 THIAZOLOPYRIMIDONES AS INHIBITORS OF DDR1/2 AND THERAPEUTIC USES THEREOF Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2022-07-28 WO disclosed